Display options
Cite
Nakanjako D, Kiragga A, Ibrahim F, et al. Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther. 2008;5:23doi: 10.1186/1742-6405-5-23.
Nakanjako, D., Kiragga, A., Ibrahim, F., Castelnuovo, B., Kamya, M. R., & Easterbrook, P. J. (2008). Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS research and therapy, 523. https://doi.org/10.1186/1742-6405-5-23
Nakanjako, Damalie, et al. "Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance." AIDS research and therapy vol. 5 (2008): 23. doi: https://doi.org/10.1186/1742-6405-5-23
Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, Easterbrook PJ. Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther. 2008 Oct 28;5:23. doi: 10.1186/1742-6405-5-23. PMID: 18957083; PMCID: PMC2605744.
Copy Download .nbib Format: NLM
Share it on

AIDS Res Ther. 2008 Oct 28;5:23. doi: 10.1186/1742-6405-5-23.

Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance.

AIDS research and therapy

Damalie Nakanjako, Agnes Kiragga, Fowzia Ibrahim, Barbara Castelnuovo, Moses R Kamya, Philippa J Easterbrook

Affiliations

  1. Infectious Diseases Institute, Facluty of Medicine, Makerere University Kampala, Uganda. [email protected]

PMID: 18957083 PMCID: PMC2605744 DOI: 10.1186/1742-6405-5-23

Abstract

BACKGROUND: A proportion of individuals who start antiretroviral therapy (ART) fail to achieve adequate CD4 cell reconstitution despite sustained viral suppression. We determined the frequency and clinical significance of suboptimal CD4 reconstitution despite viral suppression (SO-CD4) in an urban HIV research cohort in Kampala, Uganda.

METHODS: We analyzed data from a prospective research cohort of 559 patients initiating ART between 04/04-04/05. We described the patterns of SO-CD4 both in terms of:- I) magnitude of CD4 cell increase (a CD4 count increase < 50 CD4 cells/microl at 6 months, <100 cells/microl at 12 months; and <200 cells/microl at 24 months of ART) and II) failure to achieve a CD4 cell count above 200 cells/microl at 6,12 and 24 months of ART. Using criteria I) we used logistic regression to determine the predictors of SO-CD4. We compared the cumulative risk of clinical events (death and/or recurrent or new AIDS-defining illnesses) among patients with and without SO-CD4.

RESULTS: Of 559 patients initiating ART, 386 (69%) were female. Median (IQR) age and baseline CD4 counts were 38 yrs (33-44) and 98 cells/microl (21-163) respectively; 414 (74%) started a d4T-based regimen (D4T+3TC+NVP) and 145 (26%) a ZDV-based regimen (ZDV+3TC+EFV). After 6, 12 and 24 months of ART, 380 (68%), 339 (61%) and 309 (55%) had attained and sustained HIV-RNA viral suppression. Of these, 78 (21%), 151 (45%) and 166 (54%) respectively had SO-CD4 based on criteria I), and 165(43%), 143(42%) and 58(19%) respectively based on criteria II). With both criteria combined, 56 (15%) and 129 (38%) had SO-CD4 at 6 and 12 months respectively. A high proportion (82% and 58%) of those that had SO-CD4 at 6 months (using criteria I) maintained SO-CD4 at 12 and 24 months respectively. There were no statistically significant differences in the incidence of clinical events among patients with [19/100PYO (12-29)] and without SO-CD4 [23/100PYO (19-28)].

CONCLUSION: Using criteria I), the frequency of SO-CD4 was 21% at 6 months. Majority of patients with SO-CD4 at 6 months maintained SO-CD4 up to 2 years. We recommend studies of CD4 T-cell functional recovery among patients with SO-CD4.

References

  1. Clin Infect Dis. 2008 Jun 15;46(12):1911-2 - PubMed
  2. Clin Infect Dis. 2008 May 15;46(10):1598-600 - PubMed
  3. HIV Med. 2008 May;9(5):300-6 - PubMed
  4. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8 - PubMed
  5. AIDS. 2008 Mar 12;22(5):643-5 - PubMed
  6. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):202-5 - PubMed
  7. Afr Health Sci. 2007 Sep;7(3):124-8 - PubMed
  8. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93 - PubMed
  9. HIV Med. 2007 Sep;8(6):406-10 - PubMed
  10. AIDS. 2007 May 11;21(8):939-46 - PubMed
  11. J Acquir Immune Defic Syndr. 2007 May 1;45(1):52-9 - PubMed
  12. Clin Infect Dis. 2007 Feb 1;44(3):441-6 - PubMed
  13. Clin Infect Dis. 2006 Sep 15;43(6):770-6 - PubMed
  14. AIDS Rev. 2006 Apr-Jun;8(2):88-97 - PubMed
  15. BMC Infect Dis. 2006;6:59 - PubMed
  16. Lancet. 2005 Nov 26;366(9500):1831-2 - PubMed
  17. AIDS. 2005 Dec 2;19(18):2141-8 - PubMed
  18. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):288-93 - PubMed
  19. Lancet. 2005 Jul 30-Aug 5;366(9483):378-84 - PubMed
  20. Clin Infect Dis. 2005 Aug 1;41(3):361-72 - PubMed
  21. HIV Med. 2005 Mar;6(2):140-3 - PubMed
  22. J Infect Dis. 2005 Mar 1;191(5):694-701 - PubMed
  23. Blood. 1999 Aug 1;94(3):1021-7 - PubMed
  24. AIDS. 1998 May 7;12(7):745-50 - PubMed
  25. AIDS. 2003 Sep 5;17(13):1881-8 - PubMed
  26. HIV Med. 2003 Jul;4(3):255-62 - PubMed
  27. Lancet. 2002 Jul 6;360(9326):34-40 - PubMed
  28. AIDS. 2001 Sep 28;15(14):1749-56 - PubMed
  29. Scand J Infect Dis. 2001;33(8):568-71 - PubMed
  30. Ann Intern Med. 2000 Sep 19;133(6):401-10 - PubMed

Publication Types

Grant support